新冠后肺炎中血液嗜酸性粒细胞至关重要。

Blood Eosinophils Matter in Post-COVID-19 Pneumonia.

作者信息

Bernardinello Nicol, Castelli Gioele, Pasin Dylan, Grisostomi Giulia, Cola Marco, Giraudo Chiara, Cocconcelli Elisabetta, Cattelan Annamaria, Spagnolo Paolo, Balestro Elisabetta

机构信息

Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova University Hospital, 35128 Padova, Italy.

Infectious Diseases Unit, Department of Internal Medicine, Azienda Ospedaliera Universitaria di Padova, 35128 Padova, Italy.

出版信息

Diagnostics (Basel). 2024 Oct 18;14(20):2320. doi: 10.3390/diagnostics14202320.

DOI:10.3390/diagnostics14202320

PMID:39451643

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11506628/

Abstract

BACKGROUND

Even after the development of vaccines, SARS-CoV-2 continues to cause severe pneumonia all over the world. Consequently, in order to improve the management of patients and optimize the use of resources, predictors of disease severity and lung complications after COVID-19 pneumonia are urgently needed. Blood cell count is an easily available and reproducible biomarker. With this study, we aimed to explore the role of eosinophils in predicting disease behavior and pulmonary sequelae at first follow-up with computed tomography (CT).

METHODS

we evaluated blood cell count and other inflammatory markers, both at baseline and during hospitalization, in a large population of hospitalized COVID-19 patients.

RESULTS

327 patients were finally enrolled, 214 were classified as low-intensity medical care (LIMC) and 113 as high-intensity medical care. Eosinophils were higher at discharge in the HIMC group [0.1 (0-0.72) vs. 0.05 (0-0.34) × 109/L; < 0.0001]. Moreover, in the multivariable analysis, age ≥ 62 years (OR 1.76 (1.05-2.8) = 0.03) and Δ eosinophils ≥ 0.05 (OR 1.75 (1.05-2.9) = 0.03) were two independent predictors of residual lung abnormalities in the whole patient population at first follow-up.

CONCLUSIONS

an eosinophil increase during hospitalization could be a potential predictor of pulmonary sequelae in surviving patients after COVID-19 pneumonia.

摘要

背景

即使在疫苗研发之后，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）仍在全球范围内导致严重肺炎。因此，为了改善患者管理并优化资源利用，迫切需要了解冠状病毒病2019（COVID-19）肺炎后疾病严重程度和肺部并发症的预测指标。血细胞计数是一种易于获取且可重复的生物标志物。通过本研究，我们旨在探讨嗜酸性粒细胞在首次计算机断层扫描（CT）随访时预测疾病行为和肺部后遗症中的作用。

方法

我们评估了大量住院COVID-19患者在基线和住院期间的血细胞计数及其他炎症标志物。

结果

最终纳入327例患者，其中214例被归类为低强度医疗护理（LIMC）组，113例为高强度医疗护理组。高强度医疗护理组出院时嗜酸性粒细胞水平更高[0.1（0 - 0.72）对0.05（0 - 0.34）×10⁹/L；P < 0.0001]。此外，在多变量分析中，年龄≥62岁（比值比[OR] 1.76[1.05 - 2.8]；P = 0.03）和嗜酸性粒细胞变化量≥0.05（OR 1.75[1.05 - 2.9]；P = 0.03）是整个患者群体在首次随访时残留肺部异常的两个独立预测因素。